

## COVID-19 prophylaxis in ophthalmology

SARS COVID-19 is a potentially lethal viral infection transmitted from the mouth, nose and eyes of infected patients. Ophthalmologists have died of this disease.<sup>[1]</sup> For eye care specialists, the new normal includes asking our patients to wear a mask, gloves and to stay at least 6 feet away.<sup>[2-5]</sup> The latter being impossible during an eye examination. The mask acts as a barrier to respiratory virion droplets coming from the mouth and nose. However, nothing but gloves can protect us from touching the patient eyes, eye lid skin and tears.<sup>[6-8]</sup>

Innovative plexiglass barriers have been devised to shield doctors and patients from respiratory droplets. However, common tasks (such as intravitreal injections) require repeated close contact that risks infection.<sup>[6-8]</sup> During close contact we rely on our personal protective equipment (e.g., N-95 respirators, nitrile gloves and protective eye wear to prevent viral transmission and infection).

Consider that pre-surgical antibiotic prophylaxis has been common in ophthalmic surgery. Povidone-Iodine (Betadine) 5% has been routinely placed onto the ocular surface prior to surgery for cataract, retinal detachment and office-based intravitreal injection.<sup>[9]</sup> Though employed to prevent bacterial infection, betadine also has antiviral properties.<sup>[9]</sup> Submitted to the Indian Journal of Ophthalmology, we present the first use of topical Hypochlorous acid 0.01% (Avenova®, NovaBay Pharmaceuticals, Emoryville, California, USA) (HOCL) as an ocular surface antiseptic. This form of HOCL 0.01% is administered in spray-form, free of sodium hypochlorite, and at a pH of 6.5-7.0. Though employed secondarily to washout betadine 5% employed prior to intravitreal injection, we found it significantly improved patient comfort and no short or long-term HOCL complications.<sup>[9]</sup>

As part of our research we compared the antiseptic properties of both betadine 5% and HOCL 0.01%. Though there existed no clinical data on the novel coronavirus-19;

**Table 1: Antimicrobial spectrum coverage for betadine 5% and HOCL 0.01%**

Microbial Species	Betadine 5% <sup>[9,11,13,14]</sup>		HOCL 0.01% <sup>[9,10,12,13]</sup>	
	Coverage	Duration of Exposure	Coverage	Duration of Exposure
Viruses				
Adenovirus	++	<1 min	+++	< 1 min
Rotavirus	+++	<1 min	+++	< 1 min
Rhinovirus	++	<1 min	+++	< 1 min
Coxsackievirus	++	<1 min	+++	< 1 min
Influenza virus	+++	<1 min	+++	< 1 min
SARS-CoV2 (COVID-19)	+++	<1 min	+++	< 1 min

+: Weak Strength; ++: Medium Strength; +++: High Strength. Data from references.<sup>[9-14]</sup> Betadine: Povidone-iodine. HOCL 0.01%: Avenova® (NovaBay Pharmaceuticals, Emoryville, California, USA)

it is clear that hypochlorous acid 0.01% (at 1 minute) was superior for inactivation of adenovirus, rhinovirus and coxsackievirus [Table 1].<sup>[9-12]</sup> In addition, HOCL 0.01% was recently found effective against SARS COVID-19 in vitro.<sup>[13]</sup>

This suggests that antiviral pre-examination prophylaxis (PEAP) is worth considering. One drop or spray (1 minute prior to examination) may provide additional protection for both eye care professionals and their patients. The drop will cover the ocular surface and the spray treats the eye lids and lashes. PEAP offers some protection for the doctor touching possibly an infected patient's tears and skin; while affording patient protection from exposure from their provider during examination.

Our paper shows that HOCL 0.01% was better tolerated than betadine 5% alone in a small case series.<sup>[9]</sup> However, in consideration of our known experience with betadine 5% and now HOCL 0.01%, it seems reasonable to consider using HOCL 0.01% alone for PEAP.

*Paul T Finger, Anthony Fam, Ankit S Tomar, Gaurav Garg, Kimberly J Chin*

The New York Eye Cancer Center, New York City, New York, USA

Correspondence to: Dr. Paul T Finger, The New York Eye Cancer Center, 115 East 61<sup>st</sup> Street, New York City, 10065, New York, USA. E-mail: pfinger@eyecancer.com

## References

1. Yu AY, Tu R, Shao X, Pan A, Zhou K, Huang J. A comprehensive Chinese experience against SARS-CoV-2 in ophthalmology. *Eye Vis* 2020;7:19.
2. Sengupta S, Honavar SG, Sachdev MS, Sharma N, Kumar A, Ram J, et al. All India Ophthalmological Society-Indian Journal of Ophthalmology consensus state on preferred practices during the COVID-19 pandemic. *Indian J Ophthalmol* 2020;68:711-24.
3. Romano MR, Monericcio A, Montalbano C, Raimondi R, Allegrini D, Ricciardelli G, et al. Facing COVID-19 in ophthalmology department. *Curr Eye Res* 2020;45:653-8.
4. Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the coronavirus outbreak: An experience from Hong Kong. *Greafes Arch Clin Exp Ophthalmol* 2020;258:1049-55.
5. Sadhu S, Agrawal R, Pyare R, Pavesio C, Zierhut M, Khatri A, et al. COVID-19: Limiting the risks for eye care professionals. *Ocul Immunol Inflamm* 2020;28:714-20.
6. Seah IYJ, Anderson DE, Kang AEZ, Wang L, Rao P, Young BE. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. *Ophthalmology* 2020;127:977-9.
7. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. *Ocul Immunol Inflamm* 2020;28:391-5.
8. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. *Lancet* 2020;395:e39.
9. Fam A, Finger PT, Tomar AS, Garg G, Chin KJ. Avenova assisted prophylaxis for intravitreal injection: A patient reported outcome measure (PROM) study. Submitted to *Indian J Ophthalmol*.

10. Available from: <https://novabay.com/products/avenova/>. [Last accessed on 2020 Sep 09].
11. Kawana R, Kitamura T, Nakagomi O, Matsumoto I, Arita M, Yoshihara N, *et al.* Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. *Dermatology* 1997;195(Suppl 2):29-35.
12. Kim HJ, Lee JG, Kang JW, Cho HJ, Kim HS, Byeon HK, *et al.* Effects of a low concentration hypochlorous Acid nasal irrigation solution on bacteria, fungi, and virus. *Laryngoscope* 2008;118:1862-7.
13. Wigginton KR, Pecson BM, Sigstam T, Bosshard F, Kohn T. Virus inactivation mechanisms: Impact of disinfectants on virus function and structural integrity. *Environ Sci Technol* 2012;46:12069-78.
14. Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse. *J Prosthodont* 2020;29:529-33.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
<b>Quick Response Code:</b>	<b>Website:</b> www.ijo.in
	<b>DOI:</b> 10.4103/ijo.IJO_2459_20

**Cite this article as:** Finger PT, Fam A, Tomar AS, Garg G, Chin KJ. COVID-19 prophylaxis in ophthalmology. *Indian J Ophthalmol* 2020;68:2062-3.

### About the author



Paul T. Finger, MD, is Clinical Professor of Ophthalmology at the New York University School of Medicine, Director of Ocular Tumor Services at The New York Eye Cancer Center and The New York Eye and Ear Infirmary of Mount Sinai. He is a consultant for Ophthalmic Oncology at the Manhattan Eye, Ear and Throat Hospital, NYU-Langone Medical Center and the Northwell Health System. Dr. Finger has particular interest in the diagnosis and treatment of ocular tumors, orbital disease, and ophthalmic radiation therapy. Chair of the Ophthalmic Oncology Task Force (OOTF), Dr. Finger coordinated the creation of the 7<sup>th</sup> and 8<sup>th</sup> edition staging systems for the American Joint Committee on Cancer and the Union for International Cancer Control. As OOTF Chair, Dr. Finger also developed international consensus guidelines for the American Brachytherapy Society and world registry studies for uveal melanoma, conjunctival melanoma, retinoblastoma and radiation side-effects (SORRT).